CURRENTLY AVAILABLE GLP-1RA BASED THERAPIES FOR OBESITY In 1964, it was discovered that when glucose was administered orally, more insulin was secreted than when it was injected intravenously, confirming the existence of incretin, a gastrointestinal factor that promotes insulin secretion [21]
Our study revealed a novel role for GLP-1 and its derivatives in pain relief, suggesting exendin 2029 as a promising therapeutic candidate
Liver Function Support: Its ability to inhibit glucagon release results in decreased hepatic glucose production, a feature that is integral for maintaining stable blood sugar levels
Nutrition, exercise, sleep, and stress management all influence long-term weight loss success, even while taking medication
Peer Reviewed by Rosie Warwick, BSc (Hons) RD Dietitian Rosie is an HCPC-registered clinical dietitian with experience across both paediatric and adult settings
Label also updated with clinical trials reports of dysesthesia (unpleasant or altered sense of touch)
